Camatinib (Tabrecta) is a kinase inhibitor targeting metastatic non-small cell lung cancer (NSCLC) with METex14 skipping mutation. Its efficacy has been verified in clinical trials. However, during the medication period, it is necessary to strictly follow the precautions and conduct regular monitoring of relevant indicators to help improve the therapeutic effect and reduce the risk of adverse reactions.
Precautions for Camatinib (Tabrecta) Administration
Patient Selection
Camatinib is only indicated for adult patients with metastatic NSCLC whose disease has been confirmed to have METex14 skipping mutation by an FDA-approved detection method.
Before medication, molecular testing must be performed to confirm the mutation status, so as to avoid ineffective treatment.
Drug Interactions
Strong/moderate CYP3A inducers (e.g., rifampicin, efavirenz): May reduce the plasma concentration of camatinib; concurrent use should be avoided.
Strong CYP3A inhibitors (e.g., itraconazole): May increase the exposure of camatinib; close monitoring for adverse reactions is required.
Drugs that are substrates of CYP1A2, P-gp, or BCRP (e.g., caffeine, digoxin, rosuvastatin): Dosage adjustment of these drugs is necessary when used in combination with camatinib.
Administration Regimen
Recommended dosage: 400 mg orally, twice daily, with or without food.
Missed dose or vomiting: Do not make up for the missed dose; take the next dose at the originally scheduled time.
Dosage form handling: Tablets must be swallowed whole; do not break, crush, or chew them.
Management of Common Adverse Reactions
Peripheral edema (incidence rate: 52%): Mild cases can be relieved by elevating the affected limbs; dosage adjustment is required in severe cases.
Nausea/vomiting (incidence rates: 44%/28%): It is recommended to take meals in small, frequent portions or use antiemetics; if necessary, suspend medication.
Fatigue (incidence rate: 32%): Avoid driving or operating machinery, and appropriately adjust the intensity of activities.
Special Risk Prevention and Control
Interstitial lung disease (ILD)/pneumonitis: The incidence rate is 4.5%, and it may be life-threatening. If new or worsening respiratory symptoms such as dyspnea, cough, or fever occur, discontinue the drug immediately and seek medical attention.
Hepatotoxicity: 13% of patients experience elevated ALT/AST levels. Liver function should be monitored regularly before and during treatment, and dosage adjustment is required if abnormalities occur.
Photosensitivity reaction: Animal studies have shown potential phototoxicity; patients are advised to take sun protection measures (e.g., using sunscreen, wearing protective clothing).
Monitoring for Camatinib (Tabrecta) Administration
Efficacy Monitoring
Imaging evaluation: Tumor response should be assessed by CT or MRI every 6–8 weeks, and efficacy should be determined in accordance with the RECIST 1.1 criteria.
Symptom tracking: Pay attention to changes in tumor-related symptoms such as dyspnea and pain.
Safety Monitoring
Liver function: Before treatment and in the early stage of treatment, ALT, AST, and bilirubin should be tested every 2 weeks; after 3 months, the frequency can be reduced to once a month.
Renal function: Creatinine should be monitored at baseline and during treatment, especially in patients with moderate renal impairment (CLcr 30–59 mL/min).
Hematological indicators: Regularly check lymphocytes, hemoglobin, and other indicators to be alert to the risks of infection or anemia.
